Based on cost-effectiveness analysis and sensitivity analyses, the results indicate that under the WTP threshold of $150,000, ELA is not a cost-effective option compared to the standard-of-care for second-line treatment of advanced or metastatic ER-positive/HER2-negative breast cancer patients in the United States. This evidence concerns the gene ESR1 and breast carcinoma.